Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:08:59 EDT Wed 30 Apr 2025
Enter Symbol
or Name
USA
CA



Q:BLRX - BIOLINE RX LTD SPON ADR EACH REP 600 ORD SHS (P/S) - https://www.biolinerx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BLRX - Q0.12.54·30.000.23.22-0.04-1.210.730963.24  3.30  3.159435.60  2.300119:24:07Mar 3115 min RT 2¢

Recent Trades - Last 10 of 96
Time ETExPriceChangeVolume
19:24:07Q3.27920.094212
16:52:20Q3.270.0851
16:05:07Q3.270.0851
16:01:33Q3.11-0.0754
16:00:02Q3.270.08566
15:56:59Q3.245-0.015600
15:56:59Q3.21-0.05100
15:56:59Q3.21-0.05100
15:56:59Q3.210.02567
15:56:59Q3.22-0.04100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-31 07:00U:BLRXNews ReleaseBioLineRx Reports 2024 Financial Results and Provides Corporate Update
2025-01-21 07:00U:BLRXNews ReleaseBioLineRx Issues Letter to Shareholders
2025-01-17 07:00U:BLRXNews ReleaseBioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
2025-01-06 08:55U:BLRXNews ReleaseBioLineRx Announces $10 Million Registered Direct Offering
2024-11-25 07:00U:BLRXNews ReleaseBioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
2024-11-21 06:30U:BLRXNews ReleaseBioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA(TM) (motixafortide) through Gamida Cell Ltd.
2024-11-20 07:19U:BLRXNews ReleaseBioLineRx to Report Third Quarter 2024 Results on November 25, 2024
2024-11-05 09:00U:BLRXNews ReleaseBioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
2024-09-17 13:01U:BLRXNews ReleaseBioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
2024-08-15 07:00U:BLRXNews ReleaseBioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
2024-08-08 07:00U:BLRXNews ReleaseBioLineRx to Report Second Quarter 2024 Results on August 15, 2024
2024-05-28 07:00U:BLRXNews ReleaseBioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
2024-05-24 07:00U:BLRXNews ReleaseBioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
2024-05-22 07:00U:BLRXNews ReleaseBioLineRx to Report First Quarter 2024 Results on May 28, 2024
2024-05-17 17:00U:BLRXNews ReleaseBioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
2024-05-06 07:00U:BLRXNews ReleaseBioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA(TM) (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024